We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

FSR:JSEFirstRand Limited Analysis

Data as of 2026-05-20 - not real-time

ZAC 8,980.00

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

FirstRand’s share price of ZAR 8,980 sits comfortably above its 20‑day (≈ZAR 8,869), 50‑day (≈ZAR 8,855) and 200‑day (≈ZAR 8,564) moving averages, underscoring a clear bullish bias. Technical momentum is reinforced by a bullish MACD crossover (positive histogram) and a neutral‑to‑slightly‑overbought RSI at 53, though trading volume has been tapering. Valuation metrics further support the case: a trailing P/E of 11.4 is well below the industry average of 16.6, and analysts’ target price of roughly ZAR 10,433 suggests about a 16% upside, even after a recent Citi downgrade and a modestly higher discount rate in fair‑value models. The balance sheet is strong, with cash (ZAR 376 bn) far exceeding debt (ZAR 112 bn), but operating cash flow is negative (‑ZAR 107 bn), highlighting a reliance on cash reserves to fund operations. High 30‑day volatility (≈28.5%) and an “Extreme Greed” sentiment index reflect a market eager for upside, yet the lack of dividend payouts and exposure to South African economic and regulatory environments temper enthusiasm.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Bullish price above key moving averages
  • Decreasing volume indicating potential short‑term weakness
  • Valuation still offers modest upside

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Strong earnings margins and 10% revenue growth
  • Significant upside to analyst target price
  • Robust cash position offsetting operating cash‑flow shortfall

Long Term

> 3 years
Neutral
Model confidence: 7/10

Key Factors

  • Sustained profitability and solid ROE (~20%)
  • Exposure to South African economic cycles and regulatory landscape
  • Absence of dividend reduces total return potential

Key Metrics & Analysis

Financial Health

Revenue Growth9.90%
Profit Margin32.78%
P/E Ratio11.4
ROE19.85%
ROA1.81%
P/B Ratio2.1
Op. Cash FlowZAC-106978000896
Industry P/E16.6

Technical Analysis

TrendBullish
RSI53.0
SupportZAC 8,678.00
ResistanceZAC 9,276.00
MA 20ZAC 8,869.00
MA 50ZAC 8,855.36
MA 200ZAC 8,563.86
MACDBullish
VolumeDecreasing
Fear & Greed Index89.82

Valuation

Target PriceZAC 10,433.44
Upside/Downside16.19%
GradeUndervalued
TypeBlend

Risk Assessment

Beta0.21
Volatility28.52%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.